Commentary
Commentary
The Compounding Pharmacy Loophole Threatens Safety And Innovation
The new class of GLP-1 medicines exemplifies both the potential of pharmaceutical innovation and the risks to future advancements from ill-considered government policies. The incredible benefits from GLP-1’s are clear – they significantly improve our health and well-being. Risks arise because current federal policies enable activities that jeopardize patient safety ...
Commentary
If Health Insurance Premiums Rise Next Year, Blame Democrats
In the ongoing government shutdown saga, Democrats continue to cast themselves as defenders of affordable health insurance… Premiums have been on a steady upward trajectory for more than a decade. Obamacare’s own diktats are why premiums have risen. Read the op-ed here.
Commentary
Lousy Medicare Insurance Is Worsening Outcomes For All Patients
Medicare’s long-term financial outlook is in dire straits. While spending is already historically high, the Congressional Budget Office (CBO) projects that, without fundamental reform, things will only get worse. According to the CBO, total government spending will grow from 23.3% of GDP in 2025 to 26.6% in 2055. Almost two-thirds ...
Commentary
How Obamacare Set In Motion Today’s Premium Crisis
Democrats are panicking about a looming 75% average increase in the out-of-pocket cost of insurance premiums next year for the roughly 6% of the population that shops for coverage on Obamacare’s exchanges. Their panic led them to shut down the government at the end of September. The increase is a ...
Commentary
Trump Delivers Mixed Results on Health Reform
Since taking office in January, President Trump has wasted little time advancing health policies he hopes will lower costs, improve quality, and promote innovation. Those are goals worth supporting, to be sure. But the results of his efforts to date have been mixed. Consider Trump’s approach to prescription drug prices. ...
Commentary
Patients Can’t Wait for Federal Action on Knock-Off Medicines
For millions of Americans, the new class of GLP-1 weight-loss drugs are as close to a miracle as modern medicine gets. Sold under brand names like Wegovy and Zepbound, these drugs have proven astoundingly successful at helping patients shed pounds. Unfortunately, a number of unscrupulous companies have sought to capitalize ...
Commentary
Direct-To-Consumer Sales Can Fulfill Trump’s Drug Pricing Promises
The Trump administration wants to enable more Americans to purchase prescription medications directly from manufacturers at transparent, discounted prices—thus collectively saving patients tens of billions of dollars by cutting out middlemen in the drug supply chain. Voters overwhelmingly like the president’s idea. In a recent poll, 90% of Republican voters ...
Commentary
Shut down the enhanced Obamacare subsidies, not the government
Is it worth shutting down the government to keep billions in federal cash flowing to health insurers? That’s a question Republicans should be asking Democrats every chance they get. The minority party has brought business in Washington to a halt as part of a wrongheaded strategy to obscure the out-of-control ...
Commentary
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States. And if the British government refuses, the manufacturer may walk away from the market. The drug maker’s posture portends good news for ...
California
California’s weak job market is a cry for help. Is anyone listening?
California’s job market continues to suffer from largely self-inflicted wounds, despite the fact that the overall economy is growing. In April, Gov. Gavin Newsom projected that California’s economy had grown larger than Japan’s, making it the fourth largest in the world (if it were its own economy, which it’s not). ...
The Compounding Pharmacy Loophole Threatens Safety And Innovation
The new class of GLP-1 medicines exemplifies both the potential of pharmaceutical innovation and the risks to future advancements from ill-considered government policies. The incredible benefits from GLP-1’s are clear – they significantly improve our health and well-being. Risks arise because current federal policies enable activities that jeopardize patient safety ...
If Health Insurance Premiums Rise Next Year, Blame Democrats
In the ongoing government shutdown saga, Democrats continue to cast themselves as defenders of affordable health insurance… Premiums have been on a steady upward trajectory for more than a decade. Obamacare’s own diktats are why premiums have risen. Read the op-ed here.
Lousy Medicare Insurance Is Worsening Outcomes For All Patients
Medicare’s long-term financial outlook is in dire straits. While spending is already historically high, the Congressional Budget Office (CBO) projects that, without fundamental reform, things will only get worse. According to the CBO, total government spending will grow from 23.3% of GDP in 2025 to 26.6% in 2055. Almost two-thirds ...
How Obamacare Set In Motion Today’s Premium Crisis
Democrats are panicking about a looming 75% average increase in the out-of-pocket cost of insurance premiums next year for the roughly 6% of the population that shops for coverage on Obamacare’s exchanges. Their panic led them to shut down the government at the end of September. The increase is a ...
Trump Delivers Mixed Results on Health Reform
Since taking office in January, President Trump has wasted little time advancing health policies he hopes will lower costs, improve quality, and promote innovation. Those are goals worth supporting, to be sure. But the results of his efforts to date have been mixed. Consider Trump’s approach to prescription drug prices. ...
Patients Can’t Wait for Federal Action on Knock-Off Medicines
For millions of Americans, the new class of GLP-1 weight-loss drugs are as close to a miracle as modern medicine gets. Sold under brand names like Wegovy and Zepbound, these drugs have proven astoundingly successful at helping patients shed pounds. Unfortunately, a number of unscrupulous companies have sought to capitalize ...
Direct-To-Consumer Sales Can Fulfill Trump’s Drug Pricing Promises
The Trump administration wants to enable more Americans to purchase prescription medications directly from manufacturers at transparent, discounted prices—thus collectively saving patients tens of billions of dollars by cutting out middlemen in the drug supply chain. Voters overwhelmingly like the president’s idea. In a recent poll, 90% of Republican voters ...
Shut down the enhanced Obamacare subsidies, not the government
Is it worth shutting down the government to keep billions in federal cash flowing to health insurers? That’s a question Republicans should be asking Democrats every chance they get. The minority party has brought business in Washington to a halt as part of a wrongheaded strategy to obscure the out-of-control ...
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States. And if the British government refuses, the manufacturer may walk away from the market. The drug maker’s posture portends good news for ...
California’s weak job market is a cry for help. Is anyone listening?
California’s job market continues to suffer from largely self-inflicted wounds, despite the fact that the overall economy is growing. In April, Gov. Gavin Newsom projected that California’s economy had grown larger than Japan’s, making it the fourth largest in the world (if it were its own economy, which it’s not). ...
